Atrium Therapeutics, Inc. Common Stock
RNAAvidity Biosciences, Inc. is a biotechnology company focused on developing targeted RNA therapies using antibody-oligonucleotide conjugates. Their innovation aims to treat muscle and other diseases by delivering RNA-based therapeutics directly to specific tissues, leveraging their proprietary AOCs platform for precise and effective treatment options.
Company News
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the transactions.
Monteverde & Associates PC, a class action securities firm, is investigating four proposed mergers: The Brand House Collective's sale to Bed Bath & Beyond, Avidity Biosciences' acquisition by Novartis for $72 per share, NorthWestern Energy Group's sale to Black Hills Corp, and Two Harbors Investment Corp's merger with UWM Holdings Corporation. Th...
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involving mergers and acquisitions.
Novartis anticipates 5-6% annual sales growth from 2025-2030, raised peak sales projections for key drugs like Kisqali and Scemblix, and expects to maintain operating margins above 40% while planning significant U.S. infrastructure expansion.
Novartis reported Q3 2025 results with net sales rising 8% to $13.91 billion, driven by strong performance in key growth drugs like Kisqali and Kesimpta. The company reaffirmed its full-year guidance despite generic competition and announced a $12 billion acquisition of Avidity Biosciences.
